The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Pancreatic cancer is one of the leading causes of cancer mortality in the United States. Current therapy for pancreatic cancer involves surgery, chemotherapy, and radiation therapy; however, the 5-year survival rate remains less than 5%. New strategies for treating pancreatic cancer include targeting intracellular signaling that provides survival advantages to cancer cells. One of these targets is the transcription factor nuclear factor (NF) κB, which is activated by a variety of mechanisms. Data demonstrate that increased NF-κB activity can promote growth and tumorigenesis, inhibit apoptosis, promote angiogenesis, promote invasion and metastasis, and promote chemoresistance in pancreatic cancer. This review explores the roles of NF-JB in these processes and examines the evidence that different NF-κB-inhibiting drugs can improve the treatment of pancreatic cancer.

Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalPancreas
Volume36
Issue number3
DOIs
StatePublished - Apr 2008

Fingerprint

Pancreatic Neoplasms
Therapeutics
Neoplasms
Carcinogenesis
Transcription Factors
Radiotherapy
Survival Rate
Apoptosis
Neoplasm Metastasis
Drug Therapy
Mortality
Growth
Pharmaceutical Preparations

Keywords

  • NF-κB
  • Pancreatic cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

@article{8091209ac4c44a78a0c518bfd5942e8e,
title = "The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy",
abstract = "Pancreatic cancer is one of the leading causes of cancer mortality in the United States. Current therapy for pancreatic cancer involves surgery, chemotherapy, and radiation therapy; however, the 5-year survival rate remains less than 5{\%}. New strategies for treating pancreatic cancer include targeting intracellular signaling that provides survival advantages to cancer cells. One of these targets is the transcription factor nuclear factor (NF) κB, which is activated by a variety of mechanisms. Data demonstrate that increased NF-κB activity can promote growth and tumorigenesis, inhibit apoptosis, promote angiogenesis, promote invasion and metastasis, and promote chemoresistance in pancreatic cancer. This review explores the roles of NF-JB in these processes and examines the evidence that different NF-κB-inhibiting drugs can improve the treatment of pancreatic cancer.",
keywords = "NF-κB, Pancreatic cancer, Targeted therapy",
author = "Bryan Holcomb and Michele Yip-Schneider and C. Schmidt",
year = "2008",
month = "4",
doi = "10.1097/MPA.0b013e31815b3207",
language = "English",
volume = "36",
pages = "225--235",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy

AU - Holcomb, Bryan

AU - Yip-Schneider, Michele

AU - Schmidt, C.

PY - 2008/4

Y1 - 2008/4

N2 - Pancreatic cancer is one of the leading causes of cancer mortality in the United States. Current therapy for pancreatic cancer involves surgery, chemotherapy, and radiation therapy; however, the 5-year survival rate remains less than 5%. New strategies for treating pancreatic cancer include targeting intracellular signaling that provides survival advantages to cancer cells. One of these targets is the transcription factor nuclear factor (NF) κB, which is activated by a variety of mechanisms. Data demonstrate that increased NF-κB activity can promote growth and tumorigenesis, inhibit apoptosis, promote angiogenesis, promote invasion and metastasis, and promote chemoresistance in pancreatic cancer. This review explores the roles of NF-JB in these processes and examines the evidence that different NF-κB-inhibiting drugs can improve the treatment of pancreatic cancer.

AB - Pancreatic cancer is one of the leading causes of cancer mortality in the United States. Current therapy for pancreatic cancer involves surgery, chemotherapy, and radiation therapy; however, the 5-year survival rate remains less than 5%. New strategies for treating pancreatic cancer include targeting intracellular signaling that provides survival advantages to cancer cells. One of these targets is the transcription factor nuclear factor (NF) κB, which is activated by a variety of mechanisms. Data demonstrate that increased NF-κB activity can promote growth and tumorigenesis, inhibit apoptosis, promote angiogenesis, promote invasion and metastasis, and promote chemoresistance in pancreatic cancer. This review explores the roles of NF-JB in these processes and examines the evidence that different NF-κB-inhibiting drugs can improve the treatment of pancreatic cancer.

KW - NF-κB

KW - Pancreatic cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=41149089359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149089359&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e31815b3207

DO - 10.1097/MPA.0b013e31815b3207

M3 - Article

VL - 36

SP - 225

EP - 235

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -